Howard Welgus plans sale of 4,730 Arcutis shares

Howard Welgus filed a Form 144 indicating a proposed sale through Merrill Lynch of 4,730 shares of Arcutis Biotherapeutics common stock, with an aggregate market value of $123,834.71, on or after August 17, 2026 on NASDAQ.

Rhea-AI Filing Summary

Howard Welgus filed a Form 144 indicating a proposed sale through Merrill Lynch of 4,730 shares of Arcutis Biotherapeutics common stock, with an aggregate market value of $123,834.71, on or after August 17, 2026 on NASDAQ. The shares relate to restricted stock vesting of 634 shares on June 4, 2026 and stock option exercises of 822 shares (granted November 20, 2019), 1,019 shares (granted May 31, 2023), and 2,255 shares (granted June 14, 2024). In the prior three months, Welgus reported sales of 4,096 shares for $99,980.49 on June 15, 2026, 635 shares for $16,300.45 on June 17, 2026, and 4,730 shares for $127,284.30 on July 15, 2026.

Key Figures

Planned shares to be sold: 4,730 shares Aggregate market value of planned sale: $123,834.71 Restricted stock vesting: 634 shares +5 more

8 metrics

Planned shares to be sold 4,730 shares Common stock proposed for sale on or after August 17, 2026

Aggregate market value of planned sale $123,834.71 Value of 4,730 shares proposed for sale

Restricted stock vesting 634 shares Restricted stock vesting dated June 4, 2026

Stock option exercise 1 822 shares From stock option grant dated November 20, 2019

Stock option exercise 2 1,019 shares From stock option grant dated May 31, 2023

Stock option exercise 3 2,255 shares From stock option grant dated June 14, 2024

Sale June 15, 2026 4,096 shares for $99,980.49 Common stock sold during past 3 months

Sale July 15, 2026 4,730 shares for $127,284.30 Common stock sold during past 3 months

Key Terms

Form 144, Restricted Stock Vesting, Stock Option Exercise, aggregate market value

4 terms

Form 144 regulatory

"Howard Welgus filed a Form 144 indicating a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 06/04/2026 | Restricted Stock Vesting | Arcutis"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Stock Option Exercise financial

"Common | 11/20/2019 | Stock Option Exercise | Arcutis"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"shares of Arcutis Biotherapeutics common stock, with an aggregate market value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does ARQT’s latest Form 144 filing by Howard Welgus disclose?

The filing discloses a proposed sale of 4,730 ARQT common shares with an aggregate market value of $123,834.71, planned through Merrill Lynch on or after August 17, 2026, along with the equity awards from which these shares originated.

How many ARQT shares is Howard Welgus planning to sell under this Form 144?

Howard Welgus plans to sell 4,730 shares of Arcutis Biotherapeutics common stock. These shares are to be sold through Merrill Lynch on or after August 17, 2026 and are listed for trading on NASDAQ.

What recent ARQT share sales by Howard Welgus are reported in the past 3 months?

Welgus reported selling 4,096 shares for $99,980.49 on June 15, 2026, 635 shares for $16,300.45 on June 17, 2026, and 4,730 shares for $127,284.30 on July 15, 2026.

What equity awards are linked to the ARQT shares in Howard Welgus’s Form 144?

The shares are tied to restricted stock vesting of 634 shares on June 4, 2026 and stock option exercises of 822, 1,019, and 2,255 shares from grants dated 2019, 2023, and 2024, respectively.

Which broker and market are involved in Howard Welgus’s planned ARQT share sale?

The planned sale of 4,730 ARQT shares is to be executed through Merrill Lynch at its Columbus, Ohio office, with the securities listed for trading on NASDAQ as disclosed in the Form 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 04:28 PM Accepted by SEC EDGAR 08/17/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4730	123834.71	125691961	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			634	06/04/2026	NA
Common	11/20/2019	Stock Option Exercise	Arcutis Biotherapeutics			822	08/17/2026	Cash
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1019	08/17/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			2255	08/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	06/15/2026	4096	99980.49
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	06/17/2026	635	16300.45
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	07/15/2026	4730	127284.3

144: Remarks and Signature

Remarks
Date of Notice	08/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)